Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Export ban and fines loom as Greek liquidity crisis reaches saturation point and first company pulls out

This article was originally published in Scrip

Executive Summary

With the news that the first drug company has buckled under pressure and decided to withdraw from the Greek market comes concern that other suppliers may follow suit. Meanwhile, existing drug shortages caused by the liquidity crisis are being exacerbated by parallel exports, according to Greek state medicines organisation EOF, which has threatened to ban such activity for certain medicines and fine companies if the problem persists.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts